TDMS Study 05080-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
ALLYL GLYCIDYL ETHER
NTP Experiment-Test: 05080-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
Facility: Battelle Northwest
Chemical CAS #: 106-92-3
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5 PPM 10 PPM
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 10 3 6
Moribund 7 5 3
Survivors
Terminal Sacrifice 33 41 41
Dead 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (47) (9) (48)
Gallbladder (45) (6) (42)
Intestine Large, Colon (49) (9) (49)
Intestine Large, Rectum (50) (8) (49)
Intestine Small, Duodenum (46) (7) (46)
Intestine Small, Ileum (47) (7) (47)
Liver (50) (15) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma 4 (8%) 3 (20%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 1 (2%) 2 (13%) 1 (2%)
Hepatocellular Adenoma, Multiple 1 (2%)
Histiocytic Sarcoma 2 (4%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Mesentery (13) (4) (8)
Pancreas (49) (10) (50)
Histiocytic Sarcoma 2 (4%)
Salivary Glands (50) (9) (50)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (50) (12) (49)
Squamous Cell Papilloma 1 (2%) 1 (8%) 1 (2%)
Stomach, Glandular (49) (10) (48)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (9) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5 PPM 10 PPM
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (47) (9) (48)
Subcapsular, Adenoma 1 (2%)
Adrenal Gland, Cortex (47) (8) (48)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Adrenal Gland, Medulla (47) (7) (47)
Pheochromocytoma Malignant 1 (14%)
Islets, Pancreatic (49) (8) (48)
Pituitary Gland (44) (17) (45)
Pars Distalis, Adenoma 12 (27%) 8 (47%) 2 (4%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 2 (4%)
Thyroid Gland (50) (10) (50)
Bilateral, Follicular Cell, Carcinoma 1 (10%)
Follicular Cell, Adenoma 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (5) (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (1)
Hemangiosarcoma 1 (100%)
Ovary (49) (19) (50)
Cystadenocarcinoma 1 (2%)
Granulosa Cell Tumor NOS 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Luteoma 1 (2%)
Uterus (50) (24) (50)
Histiocytic Sarcoma 2 (4%)
Polyp Stromal 1 (4%) 1 (2%)
Sarcoma Stromal 1 (2%)
Cervix, Leiomyoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (35) (48)
Histiocytic Sarcoma 1 (2%)
Lymph Node (48) (11) (48)
Mediastinal, Histiocytic Sarcoma 1 (2%)
Renal, Histiocytic Sarcoma 1 (2%)
Lymph Node, Bronchial (38) (7) (37)
Page 3
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5 PPM 10 PPM
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Adenocarcinoma, Metastatic, Mammary Gland 1 (3%)
Histiocytic Sarcoma 2 (5%)
Lymph Node, Mandibular (42) (6) (40)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%) 1 (17%)
Histiocytic Sarcoma 2 (5%)
Spleen (50) (18) (50)
Histiocytic Sarcoma 2 (4%)
Thymus (34) (8) (42)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (35) (8) (30)
Adenocarcinoma 4 (11%) 1 (13%) 1 (3%)
Carcinoma 1 (3%)
Skin (50) (18) (50)
Fibrosarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (9) (50)
Sarcoma, Metastatic, Brain 1 (11%)
Skeletal Muscle (1) (1) (2)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (9) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Meninges, Meningioma NOS 1 (2%)
Meninges, Sarcoma 1 (2%) 1 (11%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (9) (50)
Lung (50) (9) (50)
Adenocarcinoma, Multiple, Metastatic,
Mammary Gland 1 (11%)
Adenocarcinoma, Metastatic, Mammary Gland 1 (2%)
Alveolar/Bronchiolar Adenoma 1 (11%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Fibrosarcoma, Multiple, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Multiple,
Page 4
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5 PPM 10 PPM
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Metastatic, Liver 1 (2%) 1 (11%)
Histiocytic Sarcoma 2 (4%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Ear 1 (2%)
Nose (49) (49) (50)
Hemangioma 1 (2%)
Respiratory Epithelium, Adenoma 1 (2%)
Trachea (50) (9) (49)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (2)
Squamous Cell Carcinoma 1 (50%)
Harderian Gland (5)
Adenoma 5 (100%)
Lacrimal Gland (1)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (10) (49)
Histiocytic Sarcoma 1 (2%)
Histiocytic Sarcoma, Metastatic, Uterus 1 (2%)
Urinary Bladder (47) (9) (47)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%)
Lymphoma Malignant 2 (4%) 1 (2%)
Lymphoma Malignant Lymphocytic 9 (18%) 1 (2%) 4 (8%)
Lymphoma Malignant Mixed 10 (20%) 4 (8%) 11 (22%)
Lymphoma Malignant Undifferentiated Cell 2 (4%) 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 5 PPM 10 PPM
FEMALE FEMALE FEMALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 21 31
Total Primary Neoplasms 59 29 48
Total Animals with Benign Neoplasms 14 12 15
Total Benign Neoplasms 18 13 23
Total Animals with Malignant Neoplasms 30 15 21
Total Malignant Neoplasms 40 16 23
Total Animals with Metastatic Neoplasms 5 2 2
Total Metastatic Neoplasm 10 4 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1 2
Total Uncertain Neoplasms 1 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5 PPM 10 PPM
MALE MALE MALE
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Dead 7 2 1
Moribund 5 9 3
Survivors
Terminal Sacrifice 37 39 46
Moribund 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (41) (4) (46)
Intestine Small, Duodenum (43) (10) (49)
Intestine Small, Ileum (45) (11) (49)
Intestine Small, Jejunum (44) (13) (48)
Liver (49) (19) (49)
Carcinosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 10 (20%) 4 (21%) 1 (2%)
Hepatocellular Adenoma 12 (24%) 7 (37%) 5 (10%)
Hepatocellular Adenoma, Multiple 3 (6%)
Mesentery (2) (1)
Pancreas (49) (12) (49)
Salivary Glands (49) (10) (49)
Stomach, Forestomach (50) (15) (49)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (15) (49)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (11) (50)
Heart (50) (11) (50)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (49) (11) (50)
Capsule, Carcinosarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
Adrenal Gland, Cortex (49) (11) (49)
Page 7
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5 PPM 10 PPM
MALE MALE MALE
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Adrenal Gland, Medulla (48) (10) (48)
Pheochromocytoma NOS 1 (2%)
Islets, Pancreatic (46) (10) (46)
Pituitary Gland (44) (9) (49)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (10) (49)
Follicular Cell, Adenoma 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Carcinosarcoma, Metastatic, Uncertain
Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (48) (10) (49)
Prostate (45) (11) (44)
Seminal Vesicle (47) (10) (44)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (49) (11) (50)
Lymph Node (43) (15) (45)
Mediastinal, Mesenteric, Carcinosarcoma,
Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Bronchial (29) (7) (29)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (14%)
Lymph Node, Mandibular (34) (9) (33)
Spleen (49) (16) (49)
Hemangioma 1 (6%)
Capsule, Carcinosarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
Thymus (30) (4) (31)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (17) (50)
Fibroma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5 PPM 10 PPM
MALE MALE MALE
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (11) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (19) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 2 (11%) 5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 5 (26%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (11%) 1 (2%)
Carcinosarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 1 (2%) 1 (5%)
Leiomyosarcoma 1 (2%)
Nose (50) (50) (50)
Respiratory Epithelium, Adenoma 3 (6%)
Submucosa, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1)
Sarcoma 1 (100%)
Harderian Gland (5) (2)
Adenoma 4 (80%) 2 (100%)
Sarcoma, Metastatic, Eye 1 (20%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (15) (49)
Capsule, Carcinosarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
Urinary Bladder (49) (11) (49)
Hemangiosarcoma 1 (2%)
Page 9
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5 PPM 10 PPM
MALE MALE MALE
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Lymphocytic 3 (6%)
Lymphoma Malignant Mixed 2 (4%) 5 (10%) 1 (2%)
Lymphoma Malignant Undifferentiated Cell 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05080-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ALLYL GLYCIDYL ETHER Date: 09/10/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 20:33:18
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 5 PPM 10 PPM
MALE MALE MALE
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 26 21
Total Primary Neoplasms 46 31 30
Total Animals with Benign Neoplasms 25 10 18
Total Benign Neoplasms 30 12 20
Total Animals with Malignant Neoplasms 13 18 10
Total Malignant Neoplasms 15 19 10
Total Animals with Metastatic Neoplasms 3 2 1
Total Metastatic Neoplasm 9 2 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 64322-64322/64322
--multipart-boundary--